MRPL16

Across TCGA pan-cancer cohorts, MRPL16 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MRPL16 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher MRPL16 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MRPL16 expression acts as an unfavorable survival marker, although some lineages such as COAD and PDAC show a favorable association.

COAD, PDAC, and LUAD are the cancer types where MRPL16 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	II,III,IV	1.000	0.914	.016	36	view →
PDAC	DFS	Median	II,III,IV	0.485	0.294	.003	29	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	4	view →
CCRCC	DFS	Median	All	0.904	0.588	.013	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MRPL16–COAD (DFS)

Open the COAD breakdown →